ZERO spontaneous bleeds.1* More spontaneous possibilities.

    Ever wonder what life would be like with ZERO spontaneous bleeds?Explore the possibilities with IXINITY®.

    Use IXINITY as prophylaxis for bleed protection before you need it,1 and discover the confidence that comes from proven bleed protection.


    *Previously treated patients (PTPs) receiving routine prophylactic treatment of 40 IU/kg to 70 IU/kg of IXINITY twice weekly demonstrated a median (IQR) annualized spontaneous bleeding rate (AsBR) of 0, and a median total annualized bleeding rate (ABR) of 1.52. IQR (range: 0-1.22) (N=61)1

    IXINITY resolves most bleeds with 1 infusion.

    In a clinical trial1:

    • 71% of bleeds were resolved with 1 infusion
    • Patients rated bleed control as “excellent” or “good” in 84% of all bleeds treated1

    A total of 508 bleeding episodes were treated with IXINITY.1

    IXINITY provides predictable bleed control for your active, unpredictable life.

    IXINITY® has an average incremental recovery of 98%.1 Higher recovery may allow lower doses.

    Incremental Recovery: The increase in plasma concentration per IU/kg of factor administered.2 Plasma-derived factor products have an incremental recovery close to 1 or 100%.2,3

    Selected Important Safety Information
    Your body may form inhibitors to IXINITY. An inhibitor is part of the body’s defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.

    How recovery impacts infusion dose.§

    Hypothetical example: Keith weighs 155 lb (about 70 kg), and is looking for a 50% factor IX increase (correction).


    Dose (IU)=body weight x desired factor IX increase x (1/recovery)1

    Ask your doctor to do an individual PK test to determine your recovery with IXINITY.

    IXINITY recovery is an average based on lab tests of patients in the clinical study.1 Because your actual recovery may be different, your dose may be different, too. Speak with your healthcare professional about the exact dose for you.

    §Description is not of an actual patient. Individual dose will vary. Patient with a baseline factor level of <1%.

    24-hour half-life for peak factor IX levels when you need them.

    The average terminal half-life of IXINITY® is 24 hours.1
    Individual half-life may vary.

    Peak factor level: Point when the highest concentration of factor in the blood is reached.4 Matching peak factor level timing with peak activity level may help support an active lifestyle.

    Terminal half-life: Time it takes for the drug’s activity to decrease by half after factor has been distributed throughout the body. The longer the terminal half-life, the longer factor is active in your system.4

    50% of peak factor level remains after full day.

    bar graphs

    Individual response may vary; therefore, number of days between dosing may vary.

    In a clinical trial, IXINITY was used in major surgeries1:


    • Knee and elbow joint replacements
    • Arthroscopic surgeries to remove inflamed joint tissue


    • “Expected” or “less than expected” blood loss
    • Zero transfusions during surgery
    • Bleed control rated adequate or better than adequate at 12 and 24 hours post-surgery

    98% Recovery

    24-Hour Half-Life

    Use in Surgery

    References: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; March 2024. 2. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia. 2011;17:179-184. 3. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600-3606. 4. Tracy TS. Pharmacokinetics. In: Craig CF, Stitzel RE. Modern Pharmacology With Clinical Applications. 6th ed. Hagerstown, MD: Lippincott Williams & Wilkins; 2004.



    What is IXINITY?

    IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. For children and adults, your healthcare provider may give you IXINITY for on-demand treatment and control of bleeding episodes, when you have surgery, or for routine prophylaxis to prevent bleeding episodes.

    IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.


    • You should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.

    • You should tell your healthcare provider if you have or have had medical problems, take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies, have any allergies, including allergies to hamsters, are nursing, are pregnant or planning to become pregnant, or have been told that you have inhibitors to factor IX.

    • You can experience an allergic reaction to IXINITY. Contact your healthcare provider or get emergency treatment right away if you develop a rash or hives, itching, tightness of the throat, chest pain, or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

    • Your body may form inhibitors to IXINITY. An inhibitor is part of the body's defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.

    • If you have risk factors for developing blood clots, the use of IXINITY may increase the risk of abnormal blood clots.

    • Call your healthcare provider right away about any side effects that bother you or do not go away, or if your bleeding does not stop after taking IXINITY.

    • The most common side effect that was reported with IXINITY during clinical trials was headache.

    • These are not all the side effects possible with IXINITY. You can ask your healthcare provider for information that is written for healthcare professionals.

    For more information about IXINITY, please see full Prescribing Information.

    You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit, or call 1-800-FDA-1088.